CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 112 enrolled
Drug / intervention
MP-435(dose1) + Methotrexate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01143337
NCT01143337Phase 2Completed
CompareCT.gov

A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study

Tanabe Pharma Corporation·interventional·Posted Jun 14, 2010·Updated Jan 6, 2026

In Brief

A Phase 2 clinical trial evaluating MP-435(dose1) + Methotrexate and Placebo + Methotrexate for Rheumatoid Arthritis. Completed, enrolled 112 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the Efficacy, Safety, and Pharmacokinetics of MP-435 administered for 12 weeks in subjects with rheumatoid arthritis (RA) on stable doses of Methotrexate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2010
Enrollment StartJun 1, 2010
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.1 years ago

Interventions

MP-435(dose1) + Methotrexatedrug

MP-435 dose1 + stable weekly dose of Methotrexate

Placebo + Methotrexatedrug

Placebo + stable weekly dose of Methotrexate